A BSTRACT
In comparison to classical medicines, gene therapy has the potential to mediate the highest possible level of therapeutic specifi city. Every normal or diseased cell can switch on or off a gene expression cassette in a tissue-, disease-, and time-dependent fashion, by use of specifi c transcription factors that are active only in a given unique situation. In practice, we face the problem in realizing the concept: the delivery of nucleic acids into target cells is very ineffective and presents a formidable challenge. Key issues for future developments include improved targeting, enhanced intracellular uptake, and reduced toxicity of gene vectors. The currently used classes of vectors have complementary characteristics, such as high intracellular effi ciency of viral vectors on the one hand and low immunogenicity and greater fl exibility of nonviral vectors on the other hand. The merge of viral and nonviral vector technologies is highlighted as an encouraging strategy for the future; concepts include chemically modifi ed viral vectors ( " chemo-viruses " ) and synthesis of virus-like systems ( " synthetic viruses " ). Examples for the development of vectors toward artifi cial synthetic viruses are presented.
INTRODUCTION
In gene therapy, different types of therapeutic nucleic acids may be applied to achieve various effects at the molecular genetic level ( Table 1 ). The nucleic acids are thereby mostly used to turn on or restore a gene function in a specifi c fashion (gain of gene function) using targeting strategies as explained in the following 2 paragraphs. A relatively new fi eld in gene therapy applies nucleic acids to yield loss of specifi c gene functions (loss of gene function), by turning off genes with antisense oligonucleotides or double-stranded small interfering (si)RNA. Both gain-of-function and loss-of-function ap proaches might revolutionize modern molecular medicine, provided that appropriate nucleic acid delivery and targeting technologies (vector systems) are available.
Specifi city for the target tissue may be achieved by 2 major strategies: (1) the therapeutic vector may be preferentially transported toward the target tissue, taken up by the target cells, and delivered into the nucleus of target cells (targeted delivery), or (2) the vector may be delivered into several cell types, but the carried nucleic acid is under the control of specifi c promoter/enhancer elements that allow gene transcription in the target cells only (targeted transcription).
The concept of targeted transcription was used, for example, to achieve highly specifi c gene expression in colon carcinoma cells. Specifi city was realized using synthetic promoters 1 that are activated after binding of b -catenin/T-cell factor, 2 factors that accumulate in the nucleus of colon cancer cells due to a deregulated Wnt signaling pathway. Brunori et al 2 applied this tumor-specifi c transcriptional regulation to control the production of attenuated adenoviruses. Since adenoviral replication was driven by the b -catenin/T-cell factor, viruses were produced in colon carcinoma cells only.
Initial efforts to realize the concept of targeted delivery were made about 20 years ago using nonviral vectors. 3 Since then, this concept has been applied for most vector types and, in many encouraging studies, effective and specifi c targeted delivery was demonstrated. The development of a targeted delivery system is not only essential for specifi c gene expression in the target tissue but also such delivery systems will allow the administered therapeutic dose to be reduced, thereby lessening toxic side effects and costs for the treatment. In addition, targeted delivery may be combined with other targeting strategies such as targeted transcription. Therefore, targeted delivery will present the main focus of this review. Before introducing the concept in detail, the characteristics and limitations of current viral and nonviral vector systems will be reviewed, outlining why improved targeted delivery remains the key issue.
E732
The AAPS Journal 2006; 8 (4) Article 83 (http://www.aapsj.org).
CHARACTERISTICS OF CURRENT VIRAL VECTORS
Several viral vector systems have been used for nucleic acid delivery; their main advantages and limitations are listed in Table 2 . Since it is the nature of viruses to deliver their genes into host cells, they present good candidates for the development of effective gene delivery. Natural evolution, however, optimized them for infecting and replicating their genome in the host cells, but not necessarily for survival of the transduced host cell and maintenance of the expressed genes. Nevertheless, replication-defective viruses, where viral genes were partly replaced by therapeutic genes, represent the fi rst generation of viral vectors applied in gene therapy.
Retroviral vectors and adenoviral vectors have been most commonly used in clinical trials ( www.wiley.co.uk/ genetherapy/clinical/ ). Other viruses that were used to develop viral vectors include adeno-associated virus (AAV), herpes virus, pox virus, and more recently lentivirus. Viruses in general are strong in cellular uptake and intracellular efficiency, therefore few viral particles are suffi cient for the transduction of cells. Most frequently, replication-defective viral vectors are applied that can replicate only in special producer cells but not in the host body cells. For some applications, however, viral replication after the application of viral vectors can be used to multiply the therapeutic effect. In tumor therapy, for example, attenuated replicative viruses 2 , 4 were used that can only replicate within tumor cells. The virus replication process directly kills the infected tumor cells (oncolytic viruses) and/or strongly amplifi es the copy number of the therapeutic gene carried by the viral vector.
Gene transfer activity of viral vectors is dependent on the type of virus used for transduction. Murine retroviral vectors, in contrast to lentiviral or adenoviral vectors, can transduce dividing cells only. This specifi city has been applied in clinical trials for the treatment of glioblastoma. 5 Retrovirus-producing cells were locally injected into glioblastoma, and the retroviral vectors transduced tumor cells but not nondividing normal brain cells. The transduced tumor cells expressed the therapeutic gene encoding for thymidine kinase. The produced enzyme converted the administered prodrug ganciclovir, into a cytotoxic agent locally. This concept gave encouraging results in preclinical 10 To improve viral vector safety, a strategy was to reduce the number of remaining adenoviral genes -from " fi rst generation " adenoviruses (only one early gene segment was removed) to so-called high-capacity " gutless " adenoviruses, where all viral genes have been replaced. 11 Unfortunately, even high-capacity " gutless " adenoviruses triggered host responses. 12 , 13 Such host responses are believed to be independent of the type of virus and of viral gene expression, but they are likely related to the viral infection process and to viral proteins of the vector particle. Infl ammatory, apoptotic, and immunological host responses to viruses, therefore, in general exclude repeated in vivo administration of viral vectors.
CHARACTERISTICS OF CURRENT SYNTHETIC VECTORS
Nonviral vectors 14 , 15 are more fl exible in terms of type and size of the delivered nucleic acid; a broad range from small siRNA, for interfering with gene expression, up to large artifi cial chromosomes can be used. The great advantage of nonviral vectors ( Table 2 ) is their lower immunogenicity in comparison to viral vectors, since they present no or less immunogenic proteins or peptides. Vectors are usually based on chemically defi ned lipids or polycations and can be generated protein free or using nonimmunogenic human or humanized proteins and peptides only.
The real weakness of nonviral vectors is their low effi ciency in intracellular delivery, which currently is partly compensated by administration of large amounts of vector. Direct injection of milligram-size quantities of plasmid DNA is usually well tolerated but still only yields very low levels of transfection. Nevertheless direct DNA application led to protein expression that was suffi cient for triggering immune responses and was used for human DNA vaccination trials. 16 To enhance the delivery of naked DNA, a series of strategies uses physical forces, such as electric pulses, mechanical forces, or hydrodynamic pressure. Electroporation enhanced transgene expression by 2 or 3 orders of magnitude, 17 suffi cient for stimulating strong immune responses in DNA vaccine applications. Specifi city of gene expression is obtained by the localized action of the physical fi eld applied for electroporation. It is important to note that the effi ciency of some physical methods is already very high. Hydrodynamic delivery to rodent livers was indeed so successful 18 , 19 that a similar pressure-mediated method was recently adapted to larger species. 20 In complex-based gene transfer vectors, plasmid DNA is condensed with cationic lipids (lipoplexes) or polycations (polyplexes). Although the most potent lipoplexes or polyplexes have reached effi ciencies of viral vectors at least in some in vivo applications, far more (100-to 1000-fold) gene copies per cell are required for successful transfection. Therefore, rather high systemically applied doses of plasmid DNA are used in preclinical studies (10-100 m g/mouse, which would equal 100-mg quantities for humans). Since plasmid DNA is not inert and contains immunological active sequences such as nonmethylated CpG sequences, the application of high DNA doses can negatively affect the long-term expression. 21 , 22 In addition, the cationic reagents used in lipoplexes and polyplexes can exert toxic side effects thereby limiting the doses that can be administered.
KEY STEPS FOR IMPROVED GENE DELIVERY
As described in the previous sections, viral and nonviral vectors have partly complementary characteristics, such as high intracellular delivery of viral vectors but lower immunogenicity and greater fl exibility of nonviral vectors. A combination of those complementary positive characteristics into a novel improved vector type would be desirable. Novel vector types should also provide capacities to overcome further limitations common to both viral and nonviral vectors, such as nonspecifi c interaction with blood components and nontarget cells, 23 clearance by the reticuloendothelial system, induction of signifi cant toxicity, including apoptotic and infl ammatory responses, and low vector specifi city for the target tissue.
Key steps where gene transfer vectors require optimization are listed in Table 3 . They refer to (1) improved extracellular delivery and targeting, (2) enhanced intracellular delivery and persistence of expression, and (3) reduced toxicity and host cell response. The following sections will review solution strategies that have been established to overcome both general and vector-specifi c limitations to improve gene delivery.
EXTRACELLULAR DELIVERY AND TARGETING
Because naked DNA is degraded by serum nucleases, condensation or encapsulation of DNA within vectors using viral capsids, cationic polymers, or lipids has greatly improved the stability of the delivered DNA. However both viral and nonviral vectors suffer from weak to nonexisting specifi city to the target tissue (see previous section). To increase specifi city, the concept of targeted delivery was developed, which is currently the most attractive concept to achieve specifi city and, in principle, this strategy is applicable for all current vectors.
To provide a vector with the ability to distinguish between target and nontarget tissue, cell binding ligands have to be incorporated that recognize target-specifi c cellular receptors. In addition, vector domains with undesired binding potential to blood or nontarget cells (eg, natural receptor binding proteins in viral vectors, positive surface charge in nonviral vectors) have to be shielded or removed.
During the past few years, a series of viral vectors have been engineered to avoid gene transfer through their native receptors and to redirect them to a variety of specifi c receptors. 24 Retargeting of viral vectors was performed genetically, for example, by sequence integration of retargeting ligands into the genome of the vector.
Retargeting was fi rst tested with retroviral vectors. 25 The challenge was to incorporate ligands without strongly reducing vector production and cell transduction effi ciency. This was, for example, achieved using a ligand-modifi ed envelope protein from another virus that was less sensitive to ligand incorporation. 26 Another approach was to genetically insert the ligand-modifi ed proteins, without replacing the natural envelope proteins. 27 Targeted AAV vectors have been designed by genetic incorporation of an antibody binding protein A domain, which upon attachment of the appropriate targeting antibody can redirect AAV to the desired receptors. 28 Specifi c transduction of distinct human hematopoietic cell lines was possible 28 Adenoviral vectors have been retargeted genetically by incorporation of cell binding peptides into viral coat proteins, as reviewed in Wickham. 24 Alternatively, 2-component systems have been applied, where a bifunctional recombinant bridging molecule binds to the vector and to a target cell receptor. This method confers a new targeting specifi city, as successfully demonstrated in vitro for more than 20 receptorligand pairs 24 (eg, the epidermal growth factor [EGF] receptor, 29 or the CD105 protein). 30 However
For the targeting of nonviral lipoplexes and polyplexes, various cell-targeting ligands were covalently attached to a lipid anchor (in lipoplexes) or a DNA-binding cationic polymer (in polyplexes). Targeting ligands that have been evaluated for this purpose include small chemical compounds, 31 vitamins, 32 carbohydrates, 33 peptide ligands, 34 growth factors, and proteins [35] [36] [37] or antibodies. [38] [39] [40] More details can be found in reviews by Schatzlein 41 and Wagner et al. 42 Successful in vitro targeting has been described by several groups. Transfection of target cells with targeted complexes led to signifi cantly (10-to 1000-fold) enhanced gene expression in comparison to ligand-free complexes. In addition, gene expression was strongly reduced in competition experiments with targeted complexes in the presence of free ligands. This apparent target specifi city can be misleading since interaction to other (nontarget) cells was not tested. In fact, the in vivo situation is different. Apart from a few cases where systemic targeting indeed was successful (for example, as described by Wu et al 43 ) it was found that irrespective of the presence of a targeting ligand, systemic administration of different lipoplexes and polyplexes via the tail vein of mice resulted in highest gene expression in the lung tissue; for example, see Kircheis et al. 44 In addition, gene transfer at effective DNA doses was associated with acute toxicity. Ex vivo experiments revealed that positively charged polyplexes induced aggregation of erythrocytes. It was proposed that both unspecifi c lung expression and toxicity are attributed to the aggregation of initially small polyplexes with blood components and their subsequent entrapment in the lung capillary bed. 45 Obviously the positive surface charge of many nonviral complexes prohibits specifi c gene transfer in vivo, and shielding agents have to be attached to nonviral vector particles to prevent unspecifi c interactions. The hydrophilic polymer polyethylene glycol (PEG) has been used to shield lipoplexes 32 , 46 and polyplexes. 36 , 44 , 47 PEG-shielding reduced gene transfer effi ciency of complexes, but the effi ciency was at least partly restored by incorporation of targeting ligands. Another approach used the serum protein transferrin both for surface shielding and targeting. 37 , 48 Applying such strategies, systemic targeting of tumors was demonstrated using the folic acid receptor, 32 transferrin receptor, 37 , 44 , 49 or epidermal growth factor (EGF) receptor 36 as target, providing fi rst proof-of-concept that systemic targeting is possible, at least with nonviral shielded vectors. Applying such polyplexes systemically, tumorspecifi c gene expression of tumor necrosis factor (TNF)-a as transgene and therapeutic effects were demonstrated in several mouse models. 50 , 51 Targeting effi ciencies, however, are still not perfect and transfection effi ciencies were very poor. Apparently, particle shielding is a double-edged sword: the shielding improves specifi city for the target tissue but impairs intracellular delivery and effi ciency of vector particles.
INTRACELLULAR DELIVERY AND PERSISTENCE OF GENE EXPRESSION
Once the vectors have reached the target cells, vector particles are internalized via cell fusion in the case of some enveloped viruses or via receptor-mediated endocytosis, macropinocytosis, phagocytosis, or related processes [52] [53] [54] [55] in the case of lipid-free viruses and most lipoplexes and polyplexes. For successful transgene expression, several intracellular barriers then have to be overcome ( Table 3 ) : vector particles need to survive in and escape from the endosome, traffi c through the cytoplasm toward the nucleus, enter the nucleus, and expose the DNA to the cell's transcription and translation machinery. Especially for fi rstgeneration nonviral vectors, some of these intracellular barriers present formidable hurdles. The fi rst step, intracellular uptake, can be taken rather easily by nonviral vectors, as appropriate receptor binding ligands may enhance binding and intracellular uptake of particles into endosomal vesicles; however, many formulations do not mediate subsequent release of particles to the cytosol. Although the " proton sponge " effect of polyethylenimine (PEI, see section " Optimizing Synthetic Viruses " ) is believed to contribute to endosomal release, 56 this effect is far from being suffi cient. Nuclear entry of nonviral vectors is another big hurdle, which is currently only easily overcome in rapid-dividing cells; for example, transfection of nondividing cells with lipoplexes or PEI polyplexes was several log units less effective compared with transfection of mitotic cells where the nuclear envelope had broken down. 57 , 58 In contrast, viral vectors are astonishingly effective in most steps of intracellular delivery. Adenovirus, for example, enters the cell via active endocytosis. The viral endosomal disruption function induces endosomal release. For intracellular traffi cking, the virus migrates along the cytosolic cytoskeleton toward the nucleus. Finally the virus uses active nuclear transfer of its viral genome through the nuclear pores. This process requires less than 1 hour, and less than 10 viral particles per cell are suffi cient for gene expression in both dividing and nondividing cells. From this perspective, viruses such as adenoviruses present ideal natural templates for the optimization of nonviral vectors.
When long-term maintenance of gene expression is desired, further measures will have to be taken to prevent early loss of the transgene. Transgene integration into the host cell genome allows persistence of gene expression but bears the risk of insertional oncogenesis since current viral vectors are randomly integrating. Efforts to mediate integration of nonviral vectors and to control the integration site include the use of new expression cassettes such as the Sleeping Beauty transposon/transposase system 59 and sitespecifi c bacteriophage recombinases. 60 Transgene maintenance can also be achieved using mini-chromosomes 61 , 62 or mini-circles. 63 Mini-circles are completely free of bacterial plasmid backbone sequences, which were found to induce immunostimulation and gene silencing. 21 , 22 In fi rst promising results, these mini-circles have been shown to prolong the in vivo gene expression. 63 
REDUCED TOXICITY AND REDUCED HOST CELL RESPONSE
All efforts that are made to increase the in vivo gene delivery effi ciency of vectors will allow substantial reduction of the therapeutic vector dose. This obviously will strongly reduce the acute and also the long-term toxicity of vector application. Shielding the positive surface charge of lipoplexes and polyplexes with PEG greatly reduced acute toxicity of nonviral vectors. 44 To further improve the safety profi le of nonviral vectors, excess cationic reagents that are not incorporated in the nonviral vector should be removed (see section " Generate Purifi ed Vector Particles " ), since these reagents exert significant cellular toxicity. In addition, preferentially biodegradable cationic DNA carriers [64] [65] [66] [67] [68] [69] should be applied to reduce any long-term toxicity hazards. 
CHEMICALLY MODIFIED VIRAL VECTORS AND SYNTHETIC VIRUS-LIKE SYSTEMS
As outlined in Table 2 , the currently used classes of viral and nonviral vectors have complementary strengths, such as high intracellular effi ciency of viral vectors, and high systemic potential with low immunogenicity of shielded nonviral vectors. The merge of viral and nonviral vector research efforts could be an encouraging strategy for the future optimization of both vector classes. Viral vectors may greatly benefi t from chemical modifi cations to develop chemoviruses ; nonviral vectors may benefi t from modifi cations mimicking viral intracellular delivery functions to generate synthetic viruses. In addition, hybrid strategies (including both nonviral and viral gene vector parts) may also provide interesting solutions (see Figure 1 ).
The combination of chemical and genetic modifi cation of recombinant viruses may be considered as a top-down approach. The aim is to delete all undesired viral functions from the viral vector (such as illustrated by the development of high-capacity gutless adenoviral vectors), and to mask the original surface of the virus with retargeting ligands and shielding shell/domains using chemical or recombinant procedures ( Figure 1 , left) .
Coating of adenoviral vectors with hydrophilic polymers such as PEG [70] [71] [72] or poly-N-2-hydroxypropyl-methacrylamide (pHPMA) 73 shielded the virus from interaction with its native receptor or neutralizing antibodies and the incorporated ligands enabled retargeting. A very encouraging example of systemic adenovirus retargeting was recently described. 74 PEGylated adenoviruses were retargeted using anti-E-selectin antibodies. These viruses showed longer persistence in the blood circulation compared with unmodifi ed viruses and selectively targeted infl amed skin in mice resulting in local gene expression.
For combination of genetic and chemical adenoviral vector particle modifi cations, a novel cystein-based vector platform was developed by Kreppel and colleagues. 75 They genetically introduced cysteines at solvent-exposed positions of the adenovirus fi bers. The corresponding thiol groups (36 per adenovirus) were highly reactive in controlled chemical coupling to protein ligands such as transferrin. Such particles were effi ciently targeted to the transferrin receptor pathway. This targeting concept via cysteine modifi cations could also be successfully combined with PEGylation of adenovirus amino groups, providing shielding (detargeting) against nontarget interactions.
Another strategy is to generate hybrid vectors combining viral and nonviral elements. For example, a virus particle (eg, adenovirus) can be covalently linked to a separate nonviral formulation (eg, expression plasmid) ( Figure 1 ,  center) . The viral vector genome (within the virus) and the separate nonviral gene expression cassette (outside the virus) may synergize in some applications; for example, a helper plasmid attached to the surface of the virus may activate virus replication or regulate the viral gene expression cassette. In addition, the nonviral part may be modifi ed with targeting ligands to allow retargeting of the hybrid vector, whereas the virus part may confer greatly improved intracellular effi ciency. 76 , 77 Another type of hybrid strategy incorporates a whole viral genome into a nonviral formulation. A plasmid, encoding for the conditionally replicating oncolytic adenovirus dl1520, was integrated into liposomes. 78 Like the parent virus, this plasmid generates infectious particles following transfection of p53-defective tumor cells, but in contrast to the virus, the particles can also transfect coxsackievirus and adenovirus receptor (CAR)-negative tumor cells. The antitumor effi cacy of this infectious plasmid was demonstrated with human tumor xenografts in mice after both local and intravenous administration. In contrast to oncolytic viruses, systemic activity was retained, even in the presence of neutralizing antibodies. 78 A complementary concept ( Figure 1 , right) to the top-down approach is to rebuild a new, synthetic virus based on the bottom-up approach . 15 Key questions of this concept are: (1) How many synthetic components are required to generate effi cient artifi cial viruses? (2) How do we achieve coordinate assembly of all components into one defi ned, supramolecular complex?
One of the fi rst prototypes of synthetic virus-like particles was generated by Plank et al. 33 The particles contained a targeting ligand and a membrane-active peptide to induce endosomal release. More specifi cally, the system contained a synthetic tetra-antennary carbohydrate ligand for hepatic asialoglycoprotein receptor binding and a synthetic acidic peptide analog derived from the N-terminal HA-2 subunit of infl uenza virus hemagglutinin. Both components were covalently attached to polylysine, a polycationic carrier for DNA binding. The polyplex components were found to compact DNA to small particles with virus-like dimension of ~100 nm. Application of these particles to hepatocytes resulted in effi cient, ligand-specifi c gene expression, which was highest in the presence of the endosome-destabilizing peptide. This early approach, however, displayed also clear limitations: compared with viral vector particles the system was still very ineffi cient; the complex formulation was a crude heterogeneous composition that did not contain any measures to shield the particle surface, and therefore particles aggregated with time. For the generation of artifi cial viruses, the assembly, purifi cation, and stability will be critical and challenging. Further aspects and examples relevant for development toward artifi cial viruses will be discussed in the next section.
OPTIMIZING SYNTHETIC VIRUSES
A synthetic virus-like vector, in its ideal form, should be available in defi ned, purifi ed, and stable form. After the controlled assembly to a defi ned multiplex system, particles should be purifi ed from all components used for vector preparation. In comparison to a standard nonviral vector, the artifi cial virus should respond in a more dynamic manner to alterations in their biological micro-environment such as changes in pH or disulfi de-reducing conditions, and the vector should undergo programmed structural changes compatible with the different gene delivery steps. This would result in improved shielding and targeting characteristics during systemic circulation and outside the target cell, and in enhanced intracellular traffi cking triggered by the intracellular environment. Thus, viruslike entry functions have to be activated and presented in a bioresponsive fashion. The following selected examples illustrate how to tackle upcoming challenges.
Generate Purifi ed Vector Particles
Nonviral vector formulations usually contain an excess of cationic transfection reagent that is not complexed to DNA. In previous studies, not much attention was paid to the presence of these " contaminating " reagents and their effect on the transfection process or on the overall toxicity. Boeckle et al 79 developed an effi cient method for the purifi cation of PEI/ DNA complexes using size exclusion chromatography that allowed complete removal of excess PEI (see Figure 2 ) . PEI polyplexes were chosen because of their established high effi ciency in vitro and in vivo. 80 Notably, purifi ed PEI polyplexes demonstrated low cellular and systemic toxicity. At lower DNA concentrations, gene transfer with purifi ed particles, however, was less effi cient than with polyplexes containing free PEI ( Figure 2 ) . Mechanistic studies showed that free PEI was essential for intracellular gene delivery steps. It is therefore likely that free PEI contributes to endosomal release, in agreement with recent data, 56 confi rming that both free PEI and PEI polyplexes contribute to the proton sponge mechanism of PEI, in that both lead to buffering of vesicular pH and accumulation of chloride in vesicles, which triggers endosome rupture. Therefore, the desired endosomal release activity currently mediated by free PEI might be replaced by alternative agents such as membrane-destabilizing peptides that are stably integrated into the vector.
Improved Endosomal Release Peptides
Endosomal release was found to be a major bottleneck for the majority of nonviral vectors. 33 , 77 Amongst various membrane-active peptides tested to overcome this barrier, melittin has displayed a particular strong membranedestabilizing activity and, when incorporated into PEI polyplexes, successfully enhanced gene transfer. 81 Of interest, the covalent attachment of melittin to PEI strongly infl uenced the peptide ' s membrane activity. Melittin-PEI conjugates have been synthesized with PEI covalently attached to the C or the N terminus of melittin (C-Mel-PEI or N-Mel-PEI). Although free melittin is not known to show pH-specifi c membrane activity, N-Mel-PEI was signifi cantly less lytic than C-Mel-PEI at pH 7. In contrast, at endosomal pH 5, N-Mel-PEI was more lytic than C-Mel-PEI. The differences in lytic activity depending on the microenvironment were found to have a strong effect on the biological activity of the corresponding DNA polyplexes. N-Mel-PEI polyplexes were less toxic in transfection and displayed significantly higher gene transfer effi ciency than C-Mel-PEI polyplexes. 82 The concept of targeted and endosomolytic polyplexes was extended into therapeutic studies. 83 Synthetic RNA viruses were generated containing synthetic RNA (poly IC), PEI as a condensing agent, EGF linked via a PEG spacer as targeting ligand, and covalently attached melittin (N-mel) as endosomal release agent. These polyplexes induced rapid cell killing in EGF receptor overexpressing glioblastoma cells, whereas tumor cells not overexpressing the EGF receptor were not affected. Nude mice carrying orthotopically implanted human glioblastoma tumors were treated with the synthetic RNA virus by implanting Alzet osmotic micropumps (DURECT Corp, Cupertino, CA) into the tumors. Whereas control animals died within 30 days after tumor implantation, all treated animals survived for >1 year and were completely cured. Similar results were also achieved with other EGF receptor overexpressing tumors. 83 Obviously for the endosomal release capacity of polyplexes, lytic activity at pH 5 is important, whereas lytic activity at pH 7 mediates cellular toxicity. Consistently, an acidicmodifi ed melittin analog of C-mel (CMA3) was designed to have even higher membrane activity at endosomal pH. This peptide mediated the best gene transfer activity upon incorporation into PEI polyplexes. 84 The next challenging step toward artifi cial viruses had to prove whether such peptideconjugates would enhance endosomal release of purifi ed polyplexes. For targeted delivery, PEG-shielded and EGFreceptor-targeted PEI polyplexes with or without CMA3-PEI conjugate were used. 84 After purifi cation, polyplexes with the melittin analog indeed displayed signifi cantly higher gene expression than polyplexes without melittin ( Figure 3 ).
Bioresponsive Elements
As mentioned earlier, the introduction of shielding agents such as PEG is a double-edged sword: particles with a higher degree of PEG shield show longer circulation time and better accumulation at the target site, but lower gene expression activity in the target cells. Apparently, the shield hampers intracellular uptake processes. Therefore an optimal nonviral system for systemic application must have a more dynamic character: its surface charge must be neutralized during circulation; but after entering the target cell, the membrane-interacting cationic surface should be re-exposed for effi cient gene transfer. For this purpose, Walker et al 85 introduced bioresponsive PEG-polycation conjugates with a pH-labile linkage. Pyridyl hydrazones showed the appropriate acid-dependent hydrolysis; at pH 5 and 37°C, 90% PEG conjugates hydrolyzed within 10 minutes, while at pH 7.4 the half-life was 1.5 hours. DNA particles shielded with these bioreversible PEG conjugates remain stable for at least 4 hours at neutral pH and 37°C but are expected to lose their PEG shield upon reaching endosomal pH ( Figure 4 ) . Particles with such labile PEG shield displayed up to 100-fold higher gene transfer activity in cell culture models compared with polyplexes with the analogous stable PEG shield, and 10-fold higher systemic in vivo gene transfer effi ciency in a mouse tumor model. 85 Engineering of nanoparticle structures with such dynamic virus-like domains is an encouraging direction in vector design.
CONCLUSIONS
Specifi city of gene vectors in recognizing the target cells only and exploiting the proper intracellular traffi cking routes are the key issues in vector optimization. These dominate many other issues; for example, any improvement in specifi city will improve effi ciency, enabling the administration of lower vector doses, which will also reduce toxicity and adverse host responses. To reach this goal, viral and nonviral vector technologies will have to be combined. First concepts already prove that this direction can be very encouraging; for example, the in vivo targeting potential of standard viral and nonviral vectors was very limited but has been greatly improved with the design of chemically modifi ed viruses 74 , 75 and synthetic virus-like systems. 15 , 85 Figure 3. Membrane-active melittin analogs for enhanced endosomal escape. An acidic melittin analog CMA3 covalently attached to PEI25kDa (CMA3-PEI25kDa) enhances luciferase gene transfer of EGF-targeted, PEG-shielded polyplexes to EGFR-Renca cells. Results with nonpurifi ed polyplexes (left graph) and SEC-purifi ed polyplexes (right graph) are shown. The polyplex formulation consists of pCMVL luciferase plasmid complexed with 10% EGF-PEG-PEI25kDa, 10% PEG20kDa-PEI25kDa, and 80% of either PEI25kDa (light bars) or CMA3-PEI25kDa (dark bars). Luciferase expression is presented in relative light units (RLU) on a logarithmic scale. PEI indicates polyethylenimine; EGF, epidermal growth factor; PEG, polyethylene glycol; and EGFR, epidermal growth factor receptor. Bioresponsive PEG conjugates are applied, which are cleavable within the endosomal pH environment, facilitating subsequent escape of polyplexes from the endosome. In comparison with the use of stable PEG conjugates, this results in strongly enhanced gene transfer in cell culture and in an in vivo tumor model. 85 PEG indicates polyethylene glycol.
